Vaccinex (VCNX) AI Stock Analysis

Compare

304 Followers

Top Page

Vaccinex

(OTC:VCNX)

Rating:45Neutral

Price Target:

$1.00

▲( 47.06% Upside)

Vaccinex's overall stock score reflects its challenging financial position, characterized by significant losses and negative equity. While there is some positive technical momentum, the poor financial performance and unattractive valuation metrics heavily impact the stock's attractiveness. The lack of earnings call data and corporate events further limits positive sentiment.

Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$1.82M

Dividend YieldN/A

Average Volume (3M)1.63K

Price to Earnings (P/E)―

Beta (1Y)2.04

Revenue Growth5.44%

EPS Growth84.28%

CountryUS

Employees23

SectorHealthcare

Sector Strength40

IndustryBiotechnology

Share Statistics

EPS (TTM)-10.12

Shares Outstanding2,676,637

10 Day Avg. Volume1,020

30 Day Avg. Volume1,627

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-1.15

Price to Sales (P/S)0.00

P/FCF Ratio-0.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Vaccinex Business Overview & Revenue Model

Company DescriptionVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

How the Company Makes MoneyVaccinex generates revenue primarily through collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development and regulatory goals, and royalties on future product sales. Additionally, Vaccinex may receive funding from government grants and research collaborations to support its clinical programs and technology development. The company's financial strategy focuses on advancing its clinical candidates through development stages to either bring them to market or out-license them to larger pharmaceutical organizations that can further develop and commercialize the products.

Vaccinex Financial Statement Overview

Summary

Vaccinex is facing significant financial challenges across all fronts. The income statement reveals consistent losses, the balance sheet shows financial instability with negative equity, and cash flows are predominantly negative. The company needs to address these issues to improve its financial health and stability.

Income Statement

Negative

The company exhibits a continuous decline in profitability, with a negative gross profit margin and net profit margin. Revenue growth is erratic, with significant fluctuations over the years. EBIT and EBITDA margins are deeply negative, indicating operational challenges in achieving profitability.

Balance Sheet

Negative

The balance sheet shows negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the company has a relatively low level of total debt. The equity ratio is negative, reflecting a severe financial risk profile.

Cash Flow

Negative

Cash flow from operations is consistently negative, indicating a struggle to generate cash from core operations. Free cash flow is also negative, although there is a noticeable reduction in the negative free cash flow trend over the recent period, suggesting a slight improvement.

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
2.00K	570.00K	100.00K	900.00K	50.00K	523.00K
	Gross Profit
-3.92M	570.00K	-107.00K	731.00K	48.00K	324.00K
	EBIT
-20.34M	-22.89M	-19.91M	-22.49M	-28.33M	-32.02M
	EBITDA
-18.55M	-19.75M	-19.61M	-21.40M	-28.05M	-31.61M
	Net Income Common Stockholders
-18.58M	-20.25M	-19.72M	-23.23M	-29.31M	-32.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.66M	1.53M	6.39M	8.59M	10.60M	2.78M
	Total Assets
0.00	3.63M	7.98M	9.84M	11.70M	4.60M
	Total Debt
0.00	247.00K	485.00K	390.00K	9.21M	0.00
	Net Debt
1.66M	-1.29M	-5.91M	-8.20M	-1.39M	-2.78M
	Total Liabilities
0.00	5.94M	2.78M	2.43M	14.31M	6.88M
	Stockholders Equity
-3.33M	-2.31M	5.19M	7.41M	-26.57M	-26.24M
Cash Flow		Free Cash Flow
-15.87M	-17.30M	-19.17M	-25.33M	-28.94M	-30.79M
	Operating Cash Flow
-15.85M	-17.23M	-19.07M	-25.30M	-28.65M	-30.71M
	Investing Cash Flow
-22.00K	-67.00K	-99.00K	-32.00K	-290.00K	14.07M
	Financing Cash Flow
18.65M	12.45M	16.98M	23.32M	36.76M	13.80M

Vaccinex Technical Analysis

Technical Analysis Sentiment

Negative

Last Price0.68

Price Trends

50DMA

0.78

Negative

100DMA

0.92

Negative

200DMA

2.33

Negative

Market Momentum

MACD

-0.02

Positive

RSI

44.53

Neutral

STOCH

8.93

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.78, and below the 200-day MA of 2.33, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.53 is Neutral, neither overbought nor oversold. The STOCH value of 8.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.

Vaccinex Risk Analysis

Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 3 New Risks

The Series A Preferred Stock ranks senior to the Company's common stock with respect to rights on the distribution of assets upon liquidation, dissolution and winding up. Q3, 2024

Shares of common stock issuable upon conversion of our Series A Preferred Stock will be dilutive to our existing shareholders upon conversion and adversely affect the market price of our common stock. Q3, 2024

The Alzheimer's Drug Discovery Foundation may be able to sell shares of our common stock in the public market, which may cause the market price of our common stock to decrease, and therefore make it more difficult to raise equity financing or issue equity as consideration in an acquisition. Q3, 2024

Vaccinex Peers Comparison

Overall Rating

UnderperformOutperform

Sector (53)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
SCNI	52 Neutral	$2.76M	1.01	138.38%	―	―	―
VCNX	45 Neutral	$1.82M	―	1406.28%	―	5.44%	84.28%
CNSP	32 Underperform	$6.01M	―	-477.53%	―	―	90.33%
QLGN	31 Underperform	$2.78M	―	367.65%	―	-100.00%	69.07%
GLTO	29 Underperform	$3.95M	―	-91.32%	―	―	48.81%
NCNA	28 Underperform	$215.90K	―	-183.07%	―	―	35.70%

* Healthcare Sector Average

Performance Comparison

VCNX

Vaccinex

0.68

-4.33

-86.43%

SCNI

Scinai Immunotherapeutics

2.76

-0.99

-26.40%

QLGN

Qualigen Therapeutics

3.77

-10.33

-73.26%

NCNA

Nucana

0.04

-3.59

-98.90%

CNSP

CNS Pharmaceuticals

1.10

-511.15

-99.79%

GLTO

Galecto

2.99

-12.59

-80.81%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.